Condition
Gastric or Esophagogastric Junction Adenocarcinoma
Total Trials
4
Recruiting
3
Active
4
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
50%
2 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
4Total
P 2 (2)
P 3 (2)
Trial Status
Recruiting3
Active Not Recruiting1
Clinical Trials (4)
Showing 4 of 4 trials
NCT07569068Phase 2RecruitingPrimary
Neoadjuvant Tislelizumab + LM-302 + S-1 or Tislelizumab + SOX for CLDN18.2-Positive Gastric/GEJ Adenocarcinoma
NCT07556640Phase 2Recruiting
LM-302 and S-1 Plus Intraperitoneal Paclitaxel With or Without Cadonilimab for Claudin 18.2-positive Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis: a Prospective, Exploratory Study
NCT05180734Phase 3Active Not RecruitingPrimary
PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer
NCT05978050Phase 3RecruitingPrimary
Nimotuzumab Combined With Paclitaxel for Recurrent Metastatic Gastric or Esophagogastric Junction Adenocarcinoma
Showing all 4 trials